Legend Biotech Corp
20-F
March 10, 2026
Key Highlights
- CARVYKTI's 2024 approval for second-line multiple myeloma (2LMM) significantly e...
- Anticipated CARVYKTI approval in Japan by 2025 promises to unlock another major ...
- A new strategic collaboration with Novartis, initiated in late 2023, diversifies...
Read Analysis
🤖 AI Generated